

ENDO INTERNATIONAL

COMPANY OVERVIEW

Endo International plc (NasdaqGS: ENDP, “Endo”) is a specialty pharmaceutical company that manufactures and sells branded and generic pharmaceuticals in the United States, Canada and internationally. Endo operates through three divisions: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, and International Pharmaceuticals. Each segment offers a variety of products. Endo was founded in 1920 and is headquartered in Dublin, Ireland.



OBJECTIVE & PROCESS

Endo engaged Bourne Partners to explore strategic alternatives regarding its Huntsville, Alabama, manufacturing site and related assets including a portfolio of ANDAs. The deal team initially evaluated the prospect of selling the facility and assets as an operating business. After assessing the market, Endo and Bourne determined Endo’s objectives would best be met by running a bifurcated process to sell the real estate and assets via multiple, separate transactions.

PASSION + PRECISION

| SENSIBILITY + LEADERSHIP

| TENACITY + HUSTLE



Endo engaged Bourne Partners to divest its Huntsville, AL, manufacturing site and related assets. After initially evaluating the market, it was determined the best path would be to sell off the various assets in a series of transactions.

LATE 2017



Endo sells an oral liquid and semi-solid basket of 23 approved and one pending drug product applications to Lannett in the second quarter of 2018 for an upfront payment plus future milestones.

Q2 2018



Endo consummates a second deal with an undisclosed counterparty for the majority of the oral solid ANDAs for an undisclosed value later in the second quarter of 2018.

Q2 2018



Endo divests the real estate, buildings, and remaining equipment of the Huntsville, Alabama, site for an undisclosed amount in the fourth quarter of 2018 to a consortium of buyers led by Federal Equipment.

Q4 2018

KNOWLEDGE + EXPERIENCE

| STRATEGY + AGILITY

| INSIGHT + ACTION

“I have had numerous interactions with the Bourne Partners M&A advisory team over the years. Their straightforward advice and thorough knowledge of the pharma / pharma services sector led us to [three] successful transactions. I would recommend them as a lead advisor to anyone seeking a specialist in the industry.”

- Paul Campanelli, Chief Executive Officer, Endo International plc